Dermata TherapeuticsDRMA
13F holders, Q2 2025 (June 30)10holders +2
3new positions
1sold out
$0.59avg. 13F price*
At the end of Q2 2025, 10 institutions reported holding Dermata Therapeutics Inc. (DRMA) in their 13F filings, up 2 from Q1 2025. 3 opened new positions and 1 sold out. The largest holders were Armistice Capital, LLC ($188K), UBS Group AG ($53K) and XTX Topco Ltd ($20K).
- Company
- Dermata Therapeutics Inc.
- CUSIP
- 249845405
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $29K |
| Exits | 1 | $2K |
All 13F filers, Q1 2025 → Q2 2025: 80,462 shares bought and 90,821 shares sold, net −10,359 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Armistice Capital, LLC | 0.01% | Reduce -21.6% | 322,179 | $188K |
| UBS Group AG | 0.00% | Add +29.4% | 90,955 | $53K |
| XTX Topco Ltd | 0.00% | New | 34,492 | $20K |
| Geode Capital Management, LLC | 0.00% | Add +34.2% | 27,385 | $16K |
| Two Sigma Securities, LLC | 0.00% | New | 14,724 | $9K |
| Jones Financial Companies LLLP | 0.00% | No change | 12,000 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +196.1% | 5,318 | $3K |
| SBI Securities Co., Ltd. | 0.00% | Add +1.0% | 1,010 | $591 |
| Citigroup Inc. | 0.00% | New | 60 | $35 |
| Bank of America Corp. | 0.00% | Add +47.6% | 31 | $18 |
"% of holder's portfolio" is DRMA's weight in each manager's 13F, not the share of Dermata Therapeutics Inc. the manager owns.